TY - JOUR
T1 - Anabolic steroid use and body image psychopathology in men
T2 - delineating between appearance- versus performance-driven motivations
AU - Murray, Stuart B.
AU - Griffiths, Scott
AU - Mond, Jonathan M.
AU - Kean, Joseph
AU - Blashill, Aaron J.
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Objective: Anabolic androgenic steroid (AAS) use has been robustly associated with negative body image, and eating- and muscularity-oriented psychopathology. However, with AAS being increasingly utilized for both appearance and athletic performance-related purposes, we investigated whether comorbid body image psychopathology varies as a function of motivation for usage. Method: Self-reported motivation for current and initial AAS use was recorded amongst 122 AAS using males, alongside measures of current disordered eating and muscle dysmorphia psychopathology. Results: Those reporting AAS for appearance purposes reported greater overall eating disorder psychopathology, F(2, 118)=7.45, p=0.001, ηp 2=0.11, and muscle dysmorphia psychopathology, F(2, 118)=7.22, p< 0.001, ηp2 =0.11, than those using AAS primarily for performance purposes. Additionally, greater dietary restraint, F(2, 116)=3.61, p=0.030, ηp2 =0.06, functional impairment, F(2, 118)=3.26, p=0.042, ηp2=0.05, and drive for size, F(2, 118)=10.76, p<0.001, ηp2=0.15, was demonstrated in those using ASS for appearance purposes. Discussion: Motivation for AAS use may be important in accounting for differential profiles of body image psychopathology amongst users. Men whose AAS use is driven primarily by appearance-related concerns may be a particularly dysfunctional subgroup.
AB - Objective: Anabolic androgenic steroid (AAS) use has been robustly associated with negative body image, and eating- and muscularity-oriented psychopathology. However, with AAS being increasingly utilized for both appearance and athletic performance-related purposes, we investigated whether comorbid body image psychopathology varies as a function of motivation for usage. Method: Self-reported motivation for current and initial AAS use was recorded amongst 122 AAS using males, alongside measures of current disordered eating and muscle dysmorphia psychopathology. Results: Those reporting AAS for appearance purposes reported greater overall eating disorder psychopathology, F(2, 118)=7.45, p=0.001, ηp 2=0.11, and muscle dysmorphia psychopathology, F(2, 118)=7.22, p< 0.001, ηp2 =0.11, than those using AAS primarily for performance purposes. Additionally, greater dietary restraint, F(2, 116)=3.61, p=0.030, ηp2 =0.06, functional impairment, F(2, 118)=3.26, p=0.042, ηp2=0.05, and drive for size, F(2, 118)=10.76, p<0.001, ηp2=0.15, was demonstrated in those using ASS for appearance purposes. Discussion: Motivation for AAS use may be important in accounting for differential profiles of body image psychopathology amongst users. Men whose AAS use is driven primarily by appearance-related concerns may be a particularly dysfunctional subgroup.
KW - anabolic androgenic steroids
KW - eating disorders
KW - muscle dysmorphia
KW - body image
UR - http://www.scopus.com/inward/record.url?scp=84977616207&partnerID=8YFLogxK
U2 - 10.1016/j.drugalcdep.2016.06.008
DO - 10.1016/j.drugalcdep.2016.06.008
M3 - Article
C2 - 27364377
AN - SCOPUS:84977616207
SN - 0376-8716
VL - 165
SP - 198
EP - 202
JO - Drug and Alcohol Dependence
JF - Drug and Alcohol Dependence
ER -